Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBS10 · 1 trial · 1 indication
The primary endpoint includes the occurrence of AE's, SAE's and Major Adverse Cardiac Events (MACE) and the assessment of myocardial perfusion measured by quantitative gated SPECT MPI specifically looking at resting total severity score.
| Arm | Type | Description |
|---|---|---|
| NBS10 | EXPERIMENTAL | active treatment - CD34+ cells |
| placebo | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| NBS10 | BIOLOGICAL | dosage = 10 or more million CD34+ cells via intracoronary infusion |
| placebo | OTHER | matching placebo |
Inclusion Criteria: 1. Age 18 years or older. 2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation \> 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, ...
NBS10 is an investigational monoclonal antibody being studied for the treatment of ST Segment Elevation Myocardial Infarction, a type of heart attack. It is being developed by Lisata Therapeutics, Inc. (NASDAQ: LSTA) and is currently in Phase 2 clinical development.
NBS10 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being investigated for its potential role in treating patients who have experienced a ST Segment Elevation Myocardial Infarction.
NBS10 is being developed by Lisata Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol LSTA. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with ST Segment Elevation Myocardial Infarction.
NBS10 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial of NBS10 has been completed, with results not yet reported.
NBS10 has been studied in a Phase 2 clinical trial with the identifier NCT01495364. This trial, titled 'NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction,' was a randomized, double-blind, placebo-controlled study that enrolled 195 participants in the United States.
Yes, NBS10 is also known as AMR-001. The clinical trial NCT01495364, which evaluated NBS10 versus placebo in patients with ST Segment Elevation Myocardial Infarction, explicitly refers to the drug as NBS10 (Also Known as AMR-001).